Yan Leyfman: Umoja Biopharma has developed an in situ CAR- therapy

Yan Leyfman shared on LinkedIn:

“Umoja Biopharma CAR- therapy novel gene therapy approach to create CD19-directed CAR T-cells within the body, allowing the company to go forward with a phase 1 dose escalation trial in hematologic malignancies. An interesting approach to monitor especially on the efficacy and side effect profile standpoint.”

Source: Yan Leyfman/LinkedIn

Yan Leyfman MD, is the Co founder and executive director of MedNews Week.  He is also the Medical correspondent at OncLive. He is also the Executive Committee Member at Music Beats Cancer. He is a Clinical Researcher at Icahn School of Medicine at Mount Sinai. His research interests include oncology, Immunooncology, Cellular Therapy, and Immunotherapy.